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OBJECTIVEdTo review the evidence about the impact of hypoglycemia on patients with
diabetes that has become available since the past reviews of this subject by the American Diabetes
Association and The Endocrine Society and to provide guidance about how this new information
should be incorporated into clinical practice.
PARTICIPANTSdFive members of the American Diabetes Association and ﬁve members of
The Endocrine Society with expertise in different aspects of hypoglycemia were invited by the Chair,
who is a member of both, to participate in a planning conference call and a 2-day meeting that was
also attended by staff from both organizations. Subsequent communications took place via e-mail
and phone calls. The writing group consisted of those invitees who participated in the writing of the
manuscript. Theworkgroupmeeting was supported by educational grants to the AmericanDiabetes
Association from Lilly USA, LLC and Novo Nordisk and sponsorship to the American Diabetes
Association fromSanoﬁ. The sponsors hadno input into the development of or content of the report.
EVIDENCEdThe writing group considered data from recent clinical trials and other studies to
update the prior workgroup report. Unpublished data were not used. Expert opinion was used to
develop some conclusions.
CONSENSUS PROCESSdConsensus was achieved by group discussion during confer-
ence calls and face-to-face meetings, as well as by iterative revisions of the written document. The
document was reviewed and approved by the American Diabetes Association’s Professional
Practice Committee in October 2012 and approved by the Executive Committee of the Board
of Directors in November 2012 and was reviewed and approved by The Endocrine Society’s
Clinical Affairs Core Committee in October 2012 and by Council in November 2012.
CONCLUSIONSdThe workgroup reconﬁrmed the previous deﬁnitions of hypoglycemia in
diabetes, reviewed the implications of hypoglycemia on both short- and long-term outcomes,
considered the implications of hypoglycemia on treatment outcomes, presented strategies to
prevent hypoglycemia, and identiﬁed knowledge gaps that should be addressed by future re-
search. In addition, tools for patients to report hypoglycemia at each visit and for clinicians to
document counseling are provided.
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In 2005, the American Diabetes Asso-ciation Workgroup on Hypoglycemiareleased a report entitled “Deﬁning and
Reporting Hypoglycemia in Diabetes” (1).
In that report, recommendations were
primarily made to advise the U.S. Food
and Drug Administration (FDA) on how
hypoglycemia should be used as an end
point in studies of new treatments for di-
abetes. In 2009, The Endocrine Society
released a clinical practice guideline enti-
tled “Evaluation and Management of
Adult Hypoglycemic Disorders,” which
summarized how clinicians should man-
age hypoglycemia in patients with diabe-
tes (2). Since then, new evidence has
become available that links hypoglycemia
with adverse outcomes in older patients
with type 2 diabetes (3–6) and in children
with type 1 diabetes (7,8). To provide
guidance about how this new information
should be incorporated into clinical prac-
tice, the American Diabetes Association
and The Endocrine Society assembled a
new Workgroup on Hypoglycemia in
April 2012 to address the following ques-
tions:
1. How should hypoglycemia in diabetes
be deﬁned and reported?
2. What are the implications of hypo-
glycemia on both short- and long-term
outcomes in people with diabetes?
3. What are the implications of hypo-
glycemia on treatment targets for pa-
tients with diabetes?
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4. What strategies are known to prevent
hypoglycemia, and what are the clini-
cal recommendations for those at risk
for hypoglycemia?
5. What are the current knowledge gaps
in our understanding of hypoglyce-
mia, and what research is necessary to
ﬁll these gaps?
How should hypoglycemia in
diabetes be deﬁned and
reported?dHypoglycemia puts pa-
tients at risk for injury and death. Conse-
quently the workgroup deﬁnes iatrogenic
hypoglycemia in patients with diabetes as
all episodes of an abnormally low plasma
glucose concentration that expose the
individual to potential harm. A single
threshold value for plasma glucose concen-
tration that deﬁnes hypoglycemia in diabe-
tes cannot be assigned because glycemic
thresholds for symptoms of hypoglycemia
(among other responses) shift to lower
plasma glucose concentrations after recent
antecedent hypoglycemia (9–12) and to
higher plasma glucose concentrations in pa-
tients with poorly controlled diabetes and
infrequent hypoglycemia (13).
Nonetheless, an alert value can be
deﬁned that draws the attention of both
patients and caregivers to the potential
harm associated with hypoglycemia. The
workgroup (1) suggests that patients at
risk for hypoglycemia (i.e., those treated
with a sulfonylurea, glinide, or insulin)
should be alert to the possibility of devel-
oping hypoglycemia at a self-monitored
plasma glucosedor continuous glucose
monitoring subcutaneous glucosed
concentration of #70 mg/dL (#3.9
mmol/L). This alert value is data driven
and pragmatic (14). Given the limited
accuracy of the monitoring devices, it ap-
proximates the lower limit of the normal
postabsorptive plasma glucose concentra-
tion (15), the glycemic thresholds for acti-
vation of glucose counterregulatory
systems in nondiabetic individuals (15),
and the upper limit of plasma glucose level
reported to reduce counterregulatory re-
sponses to subsequent hypoglycemia
(11). Because it is higher than the glycemic
threshold for symptoms in both non-
diabetic individuals and those with well-
controlled diabetes (9,13,14), it generally
allows time to prevent a clinical hypoglyce-
mic episode and provides some margin for
the limited accuracy of monitoring devices
at low-glucose levels. People with diabetes
need not always self-treat at an estimated
glucose concentration of #70 mg/dL
(#3.9 mmol/L). Options other than
carbohydrate ingestion include repeating
the test in the short term, changing behavior
(e.g., avoidingdrivingor elective exercise un-
til the glucose level is higher), and adjusting
the treatment regimen. Although this alert
value has been debated (9,13,14), a plas-
ma concentration of #70 mg/dL (#3.9
mmol/L) can be used as a cut-off value in
the classiﬁcationof hypoglycemia indiabetes.
Consistent with past recommenda-
tions (1), the workgroup suggests the fol-
lowing classiﬁcation of hypoglycemia in
diabetes:
1) Severe hypoglycemia. Severe hypo-
glycemia is an event requiring assistance
of another person to actively administer
carbohydrates, glucagon, or take other
corrective actions. Plasma glucose con-
centrations may not be available during
an event, but neurological recovery fol-
lowing the return of plasma glucose to
normal is considered sufﬁcient evidence
that the event was induced by a low
plasma glucose concentration.
2) Documented symptomatic hypogly-
cemia. Documented symptomatic hypo-
glycemia is an event during which typical
symptoms of hypoglycemia are accompa-
nied by a measured plasma glucose con-
centration #70 mg/dL (#3.9 mmol/L).
3) Asymptomatic hypoglycemia. Asymp-
tomatic hypoglycemia is an event not
accompanied by typical symptoms of hy-
poglycemia but with a measured plasma
glucose concentration #70 mg/dL (#3.9
mmol/L).
4) Probable symptomatic hypoglyce-
mia. Probable symptomatic hypoglycemia
is an event during which symptoms typical
of hypoglycemia are not accompanied by a
plasma glucose determination but that was
presumably caused by a plasma glucose
concentration#70mg/dL (#3.9mmol/L).
5) Pseudo-hypoglycemia. Pseudo-
hypoglycemia is an event during which
the person with diabetes reports any of
the typical symptoms of hypoglycemia
with a measured plasma glucose concen-
tration.70mg/dL (.3.9 mmol/L) but ap-
proaching that level.
The challenge of measuring glucose
accurately
Currently, two technologies are available to
measure glucose in outpatients: capillary
measurement with point-of-care (POC)
glucose meters (self-monitored blood glu-
cose [SMBG]) and interstitial measure-
ment with continuous glucose monitors
(CGMs), both retrospective and real time.
The International Organization for Stan-
dardization (ISO) and FDA standards
require that POC meters’ analytical accu-
racy be within 20% of the actual value in
95% of samples with glucose levels $75
mg/dL and 615 mg/dL for samples
with glucose,75 mg/dL. Despite this rel-
atively large permissible variation, Freck-
mann et al. (16) found that only 15 of 27
meters on the market in Europe several
years ago met the current analytical stand-
ards of 615 mg/dL in the hypoglycemia
range, 2 of 27 met 610 mg/dL, and none
were capable of measuring 65 mg/dL.
The need for accurate meters in the
,75 mg/dL range is essential in insulin-
treated patients, whether they are outpa-
tients or inpatients, but it is less important
in those outpatients who are on medica-
tions that rarely cause hypoglycemia. In
critical care units, where the accuracy of
POC meters is particularly crucial, their
performance may be compromised by
medications (vasopressors, acetamino-
phen), treatments (oxygen), and clinical
states (hypotension, anemia) (17). Karon
et al. (18) translated these measurement
errors into potential insulin-dosing errors
using simulation modeling and found
that if there were a total measurement
error of 20%, 1- and 2-step errors in in-
sulin dose would occur 45% and 6% of
the time, respectively, in a tight glycemic
control protocol. Such imprecision may
affect the safe implementation of insulin
infusion protocols in critical care units
and may account in part for the high hy-
poglycemia rates in most trials of inpa-
tient intensive glycemic control.
Retrospective and real-time CGMs
represent an evolving technology that
has made considerable progress in overall
(point1 rate) accuracy. However, the ac-
curacy of CGMs in the hypoglycemic
range is poor as demonstrated by error
grid analysis (19,20). With existing real-
time CGMs, accuracy can be achieved
in only 60–73% of samples in the range
of 40–80 mg/dL (21,22). Because the ac-
curacy of CGMs, like POC meters, is neg-
atively affected by multiple factors in
hospitalized patients and they are cali-
brated with POC meters affected by those
same factors, CGMs are not recommended
for glycemic management in hospitalized
patients at this time (17).
What are the implications
of hypoglycemia on both
short- and long-term
outcomes in people with
diabetes?dIatrogenic hypoglycemia
is more frequent in patients with profound
endogenous insulin deﬁciencydtype
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1 diabetes and advanced type 2 diabe-
tesdand its incidence increases with the
duration of diabetes (23). It is caused by
treatment with a sulfonylurea, glinide, or
insulin and occurs about two to three
times more frequently in type 1 diabetes
than in type 2 diabetes (23,24). Event rates
for severe hypoglycemia for patients with
type 1 diabetes range from 115 (24) to 320
(23) per 100 patient-years. Severe hypo-
glycemia in patients with type 2 diabetes
has been shown to occur at rates of 35 (24)
to 70 (23) per 100 patient-years. However,
because type 2 diabetes is much more
prevalent than type 1 diabetes, most epi-
sodes of hypoglycemia, including severe
hypoglycemia, occur in people with type
2 diabetes (25).
There is no doubt that hypoglycemia
can be fatal (26). In addition to case re-
ports of hypoglycemic deaths in patients
with type 1 and type 2 diabetes, four re-
cent reports of mortality rates in series of
patients indicate that 4% (27), 6% (28),
7% (29), and 10% (30) of deaths of pa-
tients with type 1 diabetes were caused by
hypoglycemia. A temporal relationship
between extremely low subcutaneous
glucose concentrations and death in a
patient with type 1 diabetes who was
wearing a CGM device and was found
dead in bed has been reported (31). Al-
though profound and prolonged hypo-
glycemia can cause brain death, most
episodes of fatal hypoglycemia are prob-
ably the result of other mechanisms, such
as ventricular arrhythmias (26). In this
section, we will consider the effects of
hypoglycemia on the development of hy-
poglycemia unawareness and how iatro-
genic hypoglycemia may affect outcomes
in speciﬁc patient groups.
Hypoglycemia unawareness and
hypoglycemia-associated autonomic
failure
Acute hypoglycemia in patients with di-
abetes can lead to confusion, loss of
consciousness, seizures, and even death,
but how a particular patient responds to a
drop in glucose appears to depend on
how frequently that patient experiences
hypoglycemia. Recurrent hypoglycemia
has been shown to reduce the glucose level
that precipitates the counterregulatory
response necessary to restore euglycemia
during a subsequent episode of hypogly-
cemia (10–12). As a result, patients with
frequent hypoglycemia do not experience
the symptoms from the adrenergic re-
sponse to a fall in glucose until the blood
glucose reaches lower and lower levels. For
some individuals, the level that triggers the
response is below the glucose level associ-
atedwith neuroglycopenia. The ﬁrst sign of
hypoglycemia in these patients is confu-
sion, and they often must rely on the assis-
tance of others to recognize and treat low
blood glucose. Such individuals are said to
have developed hypoglycemia unaware-
ness. Defective glucose counterregulation
(the result of loss of a decrease in insulin
production and an increase in glucagon re-
lease along with an attenuated increase in
epinephrine) and hypoglycemia unaware-
ness (the result of an attenuated increase in
sympathoadrenal activity) are the compo-
nents of hypoglycemia-associated auto-
nomic failure (HAAF) in patients with
diabetes.HAAF is a form of functional sym-
pathoadrenal failure that is most often
caused by recent antecedent iatrogenic
hypoglycemia (25) and is at least partly re-
versible by scrupulous avoidance of hypo-
glycemia (32–34). Indeed, HAAF has been
shown to be maintained by recurrent iatro-
genic hypoglycemia (33,34). The develop-
ment of HAAF is associated with a 25-fold
(35) or greater (36) increased risk of severe
hypoglycemia during intensive glycemic
therapy. It is important to distinguish
HAAF from classical autonomic neuro-
pathy, which may occur as one form of
diabetic neuropathy. Impaired sympathoa-
drenal activation is generally conﬁned to
the response to hypoglycemia, and auto-
nomic activities in organs such as the heart,
gastrointestinal tract, and bladder appear to
be unaffected.
Clinically, HAAF can be viewed as
both adaptive and maladaptive. On the
one hand, patients with hypoglycemia
unawareness and type 1 diabetes appear
to perform better on tests of cognitive
function during hypoglycemia than do
patients who are able to detect hypogly-
cemia normally (37). In addition, the time
necessary for full cognitive recovery after
restoration of euglycemia appears to be
faster in patients who have hypoglycemia
unawareness than in patients with normal
detection of hypoglycemia (37). The
HAAF habituation of the sympathoadre-
nal response to recurrent hypoglycemic
stress in humans (38) may be analogous
to the phenomenon of habituation of the
hypothalamic-pituitary-adrenocortical
response to recurrent restraint stress in
rats (39). Rats subjected to recurrent
moderate hypoglycemia had less brain
cell death (40) and less mortality (41)
during or following marked hypoglyce-
mia than those not subjected to recurrent
hypoglycemia.
On the other hand, HAAF is clearly
maladaptive since defective glucose coun-
terregulation and hypoglycemia un-
awareness substantially increase the risk
of severe hypoglycemia with its morbidity
and potential mortality (26). A particu-
larly low plasma glucose concentra-
tion might trigger a robust, potentially
fatal sympathoadrenal discharge. Life-
threatening episodes of hypoglycemia
need not be frequent to be devastating.
Impact of hypoglycemia on children
with diabetes
Hypoglycemia is a common problem in
children with type 1 diabetes because of
the challenges presented by insulin dosing,
variable eating patterns, erratic activity, and
the limited ability of small children to
detect hypoglycemia. The infant, young
child, and even the adolescent typically
exhibit unpredictable feedingdnot eat-
ing all the anticipated food at a meal
and snacking unpredictably between
mealsdand have prolonged periods of
fasting overnight that increase the risk of
hypoglycemia. Selecting the correct pran-
dial dose of insulin is therefore often difﬁ-
cult. Very low insulin requirements for
basal and mealtime dosing in the infant
and young child frequently require use
of miniscule basal rates in pump therapy
and one-half unit dosing increments with
injections. Management rarely requires
the use of diluted insulin, e.g., 10 units
per mL. Infants and toddlers may not rec-
ognize the symptoms of hypoglycemia
and lack the ability to effectively commu-
nicate their distress. Caregivers must be
particularly aware that changes in behav-
ior such as a loss of tempermay be a sign of
hypoglycemia.
Puberty is associated with insulin
resistance, while at the same time the
normal developmental stages of adoles-
cence may lead to inattention to diabetes
and increased risk for hypoglycemia. As
children grow, they often have widely
ﬂuctuating levels of activity during the
day, which puts them at risk for hypo-
glycemia. Minimizing the impact of hy-
poglycemia on children with diabetes
requires the education and engagement
of parents, patients, and other caregivers
in the management of the disease (42,43).
The youngest patients are most vul-
nerable to the adverse consequences of
hypoglycemia. Ongoing maturation of
the central nervous system puts these
children at greater risk for cognitive def-
icits as a consequence of hypoglycemia
(44). Recent studies have examined the
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impact of hypoglycemia on cognitive
function and cerebral structure in chil-
dren and found that those who experi-
ence this complication before the age of
5 years seem to be more affected than
those who do not have hypoglycemia un-
til later (7). The long-term impact of hy-
poglycemia on cognition before the age of
5 years is unknown.
Impact of hypoglycemia on adults
with type 1 diabetes
Landmark data on the impact of hypo-
glycemia on adults with type 1 diabetes
come from the Diabetes Control and
Complications Trial (DCCT) and its
follow-up study, where cognition has been
systematically measured over time. In this
cohort, performance on a comprehensive
battery of neurocognitive tests at 18 years
of follow-up was the same in participants
with and without a history of severe
hypoglycemia (28). Despite such reas-
suring ﬁndings, recent investigation with
advanced imaging techniques has demon-
strated that adults with type 1 diabetes ap-
pear to call upon a greater volume of the
brain to perform a working memory task
during hypoglycemia (45). These ﬁndings
suggest that adults with type 1 diabetes
must recruit more regions to preserve
cognitive function during hypoglycemia
than adults without the disease. More
work will be necessary to understand
the signiﬁcance of these observations on
the long-term cognitive ability of adults
with type 1 diabetes.
Impact of hypoglycemia on patients
with type 2 diabetes
There is growing evidence that patients
with type 2 diabetes might be particularly
vulnerable to adverse events associated
with hypoglycemia. Over the last decade,
three large trials examined the effect of
glucose lowering on cardiovascular
events in patients with type 2 diabetes:
ACCORD (Action to Control Cardiovas-
cular Risk in Diabetes), ADVANCE (Ac-
tion in Diabetes and Vascular Disease:
Preterax and Diamicron MR Controlled
Evaluation), and VADT (Veterans Affairs
Diabetes Trial). Between them, a total of
24,000 patients with high cardiovascular
risk were randomly assigned to either in-
tensive glycemic control or standard ther-
apy (3–5). In each, subjects who were
randomly assigned to the intensive arm
experienced more episodes of hypoglyce-
mia than did those who were randomly
assigned to the standard treatment arm.
In the ACCORD trial, subjects who were
randomly assigned to the intensive arm
also experienced a 20% increase in mor-
tality, and the glycemic control study was
stopped early due to this ﬁnding. A rela-
tionship between mortality and randomi-
zation to intensive glucose control was not
observed in ADVANCE or VADT, al-
though VADT was underpowered to ex-
plore this relationship. A number of
explanations have been offered to explain
the ﬁndings of ACCORD, including
chance, greater weight gain, and speciﬁc
medication effects, but perhaps the most
convincing candidate was hypoglycemia,
which was threefold higher in the inten-
sive arm of ACCORD (4).
In the opinion of the blinded adjudi-
cation committee assigned to investigate
mortality in ACCORD, hypoglycemia was
judged to have a deﬁnite role in only one
death, a probable role in three deaths,
and a possible role in 38 deaths (46),
which represents a role in less than 10%
of the deaths recorded in the study pop-
ulation while the glycemic intervention
was active. The investigators thus suggest
that hypoglycemia at the time of death
was probably not responsible for the in-
creased mortality rate in the intensive arm
of ACCORD. Since glycemia was notmea-
sured at the time of death in any of the
ACCORD subjects, we may never know.
However, the potential lethal mechanisms
that might be provoked by hypoglycemia
could cause mortality downstream of the
hypoglycemic event, increasing the difﬁ-
culty in establishing cause and effect.
All three trials clearly demonstrated
that an episode of severe hypoglycemia
was associated with an increased risk of
subsequent mortality. In ACCORD, those
who had one or more severe hypoglyce-
mic episodes had higher rates of death
than those without such episodes across
both study arms (hazard ratio 1.41 [95%
CI 1.03–1.93]) (46). One-third of all
deaths were due to cardiovascular dis-
ease, and hypoglycemia was associated
with higher cardiovascular mortality. In
VADT, a recent severe hypoglycemic
event was the strongest independent
predictor of death at 90 days (3). In
ADVANCE, where rates of hypoglycemia
were low, a similar pattern was found
(47). Of course, in post hoc analyses a
causal relationship cannot be established
with certainty. It is possible that the asso-
ciation between hypoglycemia and death
may be merely an indicator for vulnera-
bility for death from any cause.
The relationship between hypoglyce-
mia and subsequent cognitive function in
patients with type 2 diabetes has also been
investigated. In a large population study,
hypoglycemic episodes that required hos-
pitalization or a visit to the emergency
department between 1980 and 2002 were
associated with approximately double the
risk of incident dementia after 2003 (6).
However, since the study population did
not undergo detailed tests of cognitive
function prior to 2003, it is possible that
those with incident dementia actually
had mild cognitive dysfunction prior to
experiencing the episode(s) of severe
hypoglycemia. The possibility that mild
cognitive dysfunction might increase the
risk of experiencing severe hypoglycemia
has been supported by analyses from the
ACCORD study (48). In the ACCORD
MIND (Memory IN Diabetes) study, in
which cognitive function was assessed lon-
gitudinally, no difference was noted in the
rate at which cognitive performance de-
clined over time in subjects randomly as-
signed to the intensive versus the standard
glucose arms despite the fact that they expe-
rienced three times as much hypoglycemia
(49). Future investigation will need to ad-
dress this question because the existing data
are somewhat contradictory.
Impact of hypoglycemia on the
elderly
Patients in the older age-groups are
especially vulnerable to hypoglycemia.
Epidemiological studies show that hypo-
glycemia is the most frequent metabolic
complication experienced by older adults
in the U.S. (50). Although severe hypo-
glycemia is common in older individu-
als with both type 1 and type 2 diabetes,
patients with type 2 diabetes tend to
have longer hospital stays and greater
medical costs. The most signiﬁcant pre-
dictors of this condition are advanced
age, recent hospitalization, and polyphar-
macy, as shown in a study of Tennessee
Medicare patients (51). Age-related de-
clines in renal function and hepatic en-
zyme activity may interfere with the
metabolism of sulfonylureas and insulin,
thereby potentiating their hypoglycemic
effects. The vulnerability of the elderly to
severe hypoglycemia may be partially re-
lated to a progressive age-related decrease
in b-adrenergic receptor function (52).
Age-related impairment in counterregula-
tory hormone responses has been de-
scribed in elderly patients with diabetes,
especially with respect to glucagon and
growth hormone (53). Symptoms of neu-
roglycopenia are more prevalent (54).
With the prolonged duration of type 2
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diabetes as is often seen in the elderly pa-
tient, the glucagon response to hypo-
glycemia is virtually absent (55). The
intensiﬁcation of glycemic control in the
elderly patient is associated with an in-
creased reduction in the plasma glucose
thresholds for epinephrine release and for
the appearance of hypoglycemia (56). As a
result, changes in the level of glycemic con-
trol have a marked impact on the risk of
developing hypoglycemia in the elderly.
Older adults with diabetes have a
disproportionately high number of clini-
cal complications and comorbidities, all
of which can be exacerbated by and
sometimes contribute to episodes of hy-
poglycemia. Older adults with diabetes
are at much higher risk for the geriatric
syndrome, which includes falls, inconti-
nence, frailty, cognitive impairment, and
depressive symptoms (57). The cognitive
and executive dysfunction associated
with the geriatric syndrome interferes
with the patient’s ability to perform self-
care activities appropriately and follow
the treatment regimen (58).
Tominimize the risk of hypoglycemia
in the elderly, careful education regarding
the symptoms and treatment of hypogly-
cemia, with regular reinforcement, is ex-
tremely important because of the
recognized gaps in the knowledge base
of these individuals (59). In addition, it is
important to assess the elderly for func-
tional status as part of the overall clinical
assessment in order to properly apply
individualized glycemic control goals.
Arbitrary short-acting insulin sliding
scales, which are used much too often in
long-term care facilities (60), should be
avoided, and glyburide should be discon-
tinued in favor of shorter-acting insulin
secretagogues or medications that do
not cause hypoglycemia. The recently
published 2012 Beers list of prohibited
medications in long-term care facilities
speciﬁcally lists insulin sliding scales
and glyburide as treatment modalities
that should be avoided (61). Complex
regimens requiring multiple decision
points should be simpliﬁed, especially
for patients with decreased functional sta-
tus. In addition, caregivers and staff in
long-term care facilities need to be edu-
cated on the causes and risks of hypogly-
cemia and the proper surveillance and
treatment of this condition.
Impact of hypoglycemia on
hospitalized patients
Persons with diabetes are three times
more likely to be hospitalized than those
without diabetes, and approximately 25%
of hospitalized patients (including people
without a history of diabetes) have hy-
perglycemia (62–65). Inpatient hypergly-
cemia has been associated with prolonged
hospital length of stay andwith numerous
adverse outcomes including mortality
(64,66–68). The understandable zeal to
minimize the adverse consequences of in-
patient hyperglycemia, together with the
demonstration that intensive glycemic
control improved outcomes in surgical
intensive care unit (ICU) patients (69),
led to widespread adoption of aggressive
glucose management among ICU pa-
tients. However, subsequent studies
showed that such aggressive lowering of
glycemia in the ICU is not uniformly ben-
eﬁcial, markedly increases the risk of severe
hypoglycemia, and may be associated with
increased mortality (70–74).
The true incidence and prevalence of
hypoglycemia among hospitalized pa-
tients with diabetes are not known pre-
cisely. In a retrospective study of 31,970
patients admitted to the general wards of
an academic medical center in 2007, a
total of 3,349 patients (10.5%) had at
least one episode of hypoglycemia (#70
mg/dL) (75). In another review of 5,365
inpatients admitted to ICUs, 102 (1.9%)
had at least one episode of severe hypo-
glycemia (,40 mg/dL) (76). The risk fac-
tors for inpatient hypoglycemia include
older age, presence of comorbidities, di-
abetes, increasing number of antidiabetic
agents, tight glycemic control, septic
shock, renal insufﬁciency, mechanical ven-
tilation, and severity of illness (75,76).
With regard to impact, a retrospective
analysis of 4,368 admissions involving
2,582 diabetic patients admitted to the
general ward indicated that severe hypo-
glycemia (#50 mg/dL) was associated
with increased length of stay and greater
odds of inpatient death and death within 1
year of hospital discharge (77).
Impact of hypoglycemia during
pregnancy
Maintaining blood glucose control in preg-
nancy as close to that of healthy pregnant
women is important in minimizing the
negative effects on themother and the fetus
(78). This is true for women with pregesta-
tional type 1 or type 2 diabetes, as well for
those with gestational diabetes mellitus.
Normal blood glucose levels during preg-
nancy are 20% lower than in nonpregnant
women (79),making the deﬁnition and de-
tection of hypoglycemia more challenging.
For women with type 1 diabetes, severe
hypoglycemia occurs 3–5 times more fre-
quently in the ﬁrst trimester and at a lower
rate in the third trimester when compared
with the incidence in the year preceding the
pregnancy (80). Risk factors for severe hy-
poglycemia in pregnancy include a history
of severe hypoglycemia in the preceding
year, impaired hypoglycemia awareness,
long duration of diabetes, low HbA1c
in early pregnancy, ﬂuctuating plasma
glucose levels, and excessive use of sup-
plementary insulin between meals. Sur-
prisingly, nausea and vomiting during
pregnancy did not appear to add signiﬁcant
risk. When pregnant and nonpregnant
women are compared with CGM, mild hy-
poglycemia (deﬁned by the authors as
blood glucose ,60 mg/dL) is more com-
mon in all pregnant women, but equally
so regardless of whether or not they have
diabetes, either pregestational or gesta-
tional (81). Hypoglycemia is generally
without risk for the fetus as long as the
mother avoids injury during the episode.
For women with preexisting diabetes, in-
sulin requirements rise throughout the
pregnancy and then drop precipitously at
the time of delivery of the placenta, requir-
ing an abrupt reduction in insulin dosing to
avoid postdelivery hypoglycemia. Breast-
feeding may also be a risk factor for hypo-
glycemia in women with insulin-treated
diabetes (82).
Impact of hypoglycemia on quality of
life and activities of daily living
Hypoglycemia and the fear of hypoglyce-
mia have a signiﬁcant impact on quality-
of-life measures in patients with both type
1 and type 2 diabetes (83). Nocturnal hy-
poglycemia in particular may impact
one’s sense of well-being on the following
day because of its impact on sleep quan-
tity and quality (84). Patients with recur-
rent hypoglycemia have been found to
have chronic mood disorders including
depression and anxiety (85,86), although
it is hard to establish cause and effect be-
tween hypoglycemia and mood changes.
Interpersonal relationships may suffer
as a result of hypoglycemia in patients
with diabetes. In-depth interviews of a
small group of otherwise healthy young
adults with type 1 diabetes revealed the
presence of interpersonal conﬂict includ-
ing fears of dependency and loss of con-
trol. These adults also reported difﬁculty
talking about issues related to hypoglyce-
mia with signiﬁcant others (87). This dif-
ﬁculty may carry over to their work life,
where hypoglycemia has been linked to
reduced productivity (88). Hypoglycemia
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also impairs one’s ability to drive a car
(89–91), and many jurisdictions require
documentation that severe hypoglycemia
is not occurring before persons with di-
abetes are permitted to have a license to
operate a motor vehicle (92). However,
impaired awareness of hypoglycemia
has not consistently been associated
with an increased risk of car collisions
(92–95).
What are the implications of
hypoglycemia on treatment
targets for patients with
diabetes?dThe glycemic target es-
tablished for any given patient should
depend on the patient’s age, life expec-
tancy, comorbidities, preferences, and
an assessment of how hypoglycemia
might impact his or her life. This
patient-centered approach requires that
clinicians spend time developing an indi-
vidualized treatment plan with each pa-
tient. For very young children, the risks of
severe hypoglycemia on brain develop-
ment may require a strategy that attempts
to avoid hypoglycemia at all costs. For
healthy adults with diabetes, a reasonable
glycemic goal might be the lowest HbA1c
that does not cause severe hypoglycemia,
preserves awareness of hypoglycemia,
and results in an acceptable number of
documented episodes of symptomatic
hypoglycemia. With current therapies,
a strategy that completely avoids hypogly-
cemia may not be possible in patients with
type 1 diabetes who strive to minimize
their risks of developing themicrovascular
complications of the disease. However,
glycemic goals might reasonably be re-
laxed in patients with long-standing type
1 diabetes and advanced complications or
in those who are free of complications but
have a limited life expectancy because of
another disease process. In such patients,
the glycemic goal could be to achieve glu-
cose levels sufﬁciently low to prevent
symptoms of hyperglycemia.
For patients with type 2 diabetes, the
risk of hypoglycemia depends on the
medications used (96). Early in the course
of the disease, most patients are treated
with lifestyle changes andmetformin, nei-
ther of which causes hypoglycemia.
Therefore, an HbA1c of,7% is appropri-
ate for many patients with recent-onset
type 2 diabetes. As the disease progresses,
it is likely that medications that increase
the risk of hypoglycemia will be added.
This, plus the presence of complications
or comorbidities that limit life expec-
tancy, means that glycemic goals may
need to be less aggressive. While the ben-
eﬁts of achieving an HbA1c of ,7% may
continue to be advocated for patients with
type 2 diabetes at risk for microvascular
complications and with sufﬁcient life ex-
pectancy, less aggressive targets may be
appropriate in those with known cardio-
vascular disease, extensive comorbidities,
or limited life expectancy.
Older individuals with gait imbalance
and frailty may experience a life-changing
injury if they fall during a hypoglycemia
episode, so avoiding hypoglycemia is
paramount in such patients. Patients
with cognitive dysfunction may have
difﬁculty adhering to a complicated treat-
ment strategy designed to achieve a low
HbA1c (48). Such patients will beneﬁt
from a simpliﬁcation of the treatment
strategy with a goal to prevent hypoglyce-
mia as much as possible. Furthermore,
the beneﬁts of aggressive glycemic ther-
apy in those affected are unclear.
What strategies are known
to prevent hypoglycemia,
and what are the clinical
recommendations for those
at risk for hypoglycemia?d
Recurrent hypoglycemia increases the
risk of severe hypoglycemia and the de-
velopment of hypoglycemia unawareness
and HAAF. Effective approaches known
to decrease the risk of iatrogenic hypo-
glycemia include patient education,
dietary and exercise modiﬁcations, med-
ication adjustment, careful glucose mon-
itoring by the patient, and conscientious
surveillance by the clinician.
Patient education
There is limited research related to the
inﬂuence of self-management education
on the incidence or prevention of hypo-
glycemia. However, there is clear evi-
dence that diabetes education improves
patient outcomes (97–99). As part of the
educational plan, the individual with di-
abetes and his or her domestic compan-
ions need to recognize the symptoms of
hypoglycemia and be able to treat a hypo-
glycemic episode properly with oral car-
bohydrates or glucagon. Hypoglycemia,
including its risk factors and remedia-
tion, should be discussed routinely
with patients receiving treatment with
insulin or sulfonylurea/glinide drugs, es-
pecially those with a history of recurrent
hypoglycemia or impaired awareness of
hypoglycemia. In addition, patients
must understand how their medications
work so they can minimize the risk of
hypoglycemia. Care should be taken to
educate patients on the typical pharma-
cokinetics of these medications. When
evaluating a patient’s report of hypogly-
cemia, it is important to adopt interview-
ing approaches that guide the patient
to a correct identiﬁcation of the pre-
cipitating factors of the episodes of hy-
poglycemia. Such a heuristic review of
likely factors (skipped or inadequate
meal, unusual exertion, alcohol inges-
tion, insulin dosage mishaps, etc.)
in the period prior to the event can
deepen the patient’s appreciation of the
behavioral factors that predispose to
hypoglycemia.
There is convincing evidence that
formal training programs that teach pa-
tients to replace insulin “physiologically”
by giving background and mealtime/
correction doses of insulin can reduce
the risk of severe hypoglycemia. The In-
sulin Treatment and Training programs
developed by M€uhlhauser and Berger
(100) have reported improved glycemic
control comparable with DCCT while re-
ducing the rates of severe hypoglycemia
(101,102). These programs have been
successfully delivered in other settings
(103,104) with comparable reductions
in hypoglycemic risk (105). Patients
with frequent hypoglycemia may also
beneﬁt from enrollment in a blood glu-
cose awareness training program. In
such a program, patients and their rela-
tives are trained to recognize subtle cues
and early neuroglycopenic indicators of
evolving hypoglycemia and respond to
them before the occurrence of disabling
hypoglycemia (106,107).
Dietary intervention
Patients with diabetes need to recognize
which foods contain carbohydrates and
understand how the carbohydrates in
their diet affect blood glucose. To avoid
hypoglycemia, patients on long-acting
secretagogues and ﬁxed insulin regimens
must be encouraged to follow a predict-
able meal plan. Patients on more ﬂexible
insulin regimens must know that prandial
insulin injections should be coupled to
meal times. Dissociated meal and insulin
injection patterns lead to wide ﬂuctuations
in plasma glucose levels. Patients on
any hypoglycemia-inducing medication
should also be instructed to carry carbo-
hydrates with them at all times to treat
hypoglycemia.
The best bedtime snack to prevent
overnight hypoglycemia in patients with
type 1 diabetes has been investigated
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without clear consensus (108–112).
These conﬂicting reports suggest that
the administration of bedtime snacks
may need to be individualized and be
part of a comprehensive strategy (bal-
anced diet, patient education, optimized
drug regimens, and physical activity
counseling) for the prevention of noctur-
nal hypoglycemia.
Exercise management
Physical activity increases glucose utiliza-
tion, which increases the risk of hypo-
glycemia. The risk factors for exertional
hypoglycemia include prolonged ex-
ercise duration, unaccustomed exercise
intensity, and inadequate energy supply
in relation to ambient insulinemia
(113,114). Postexertional hypoglycemia
can be prevented or minimized by careful
glucose monitoring before and after exer-
cise and taking appropriate preemptive
actions. Preexercise snacks should be in-
gested if blood glucose values indicate
falling glucose levels. Patients with diabe-
tes should carry readily absorbable carbo-
hydrates when embarking on exercise,
including sporadic house or yard work.
Because of the kinetics of rapid-acting
and intermediate-acting insulin, it may
be prudent to empirically adjust insulin
doses on the days of planned exercise, es-
pecially in patients with well-controlled
diabetes with a history of exercise-related
hypoglycemia.
Medication adjustment
Hypoglycemic episodes that are not read-
ily explained by conventional factors
(skipped or irregular meals, unaccus-
tomed exercise, alcohol ingestion, etc.)
may be due to excessive doses of drugs
used to treat diabetes. A thorough review
of blood glucose patterns may suggest
vulnerable periods of the day that man-
date adjustments to the current antidia-
betes regimen. Such adjustments may
include substitution of rapid-acting in-
sulin (lispro, aspart, glulisine) for regular
insulin, or basal insulin glargine or dete-
mir for NPH, to decrease the risk of
hypoglycemia. Continuous subcutaneous
insulin infusion offers great ﬂexibility
for adjusting the doses and administra-
tion pattern of insulin to counteract
iatrogenic hypoglycemia (115). For pa-
tients with type 2 diabetes, sulfonylureas
are the oral agents that pose the greatest
risk for iatrogenic hypoglycemia and
substitution with other classes of oral
agents or even glucagon-like peptide 1
analogs should be considered in the
event of troublesome hypoglycemia
(96). Interestingly, successful transplan-
tation of whole pancreata or isolated
pancreatic islet cells in patients with
type 1 diabetes (116–118) results in
marked improvements in glycemic
control and near abolition of iatrogenic
hypoglycemia.
Patients who develop hypoglycemia
unawareness do so because of frequent
and recurrent hypoglycemia. To avoid
such frequent hypoglycemia, adjust-
ments in the treatment regimen that
scrupulously avoid hypoglycemia are
necessary (Table 1). In published studies,
this has required frequent (almost daily)
contact between clinician and patient,
and adjustments to caloric intake and in-
sulin regimen based on blood glucose
values (10,119,120). With this ap-
proach, restoration of autonomic symp-
toms of hypoglycemia occurred within 2
weeks, and complete reversal of hypogly-
cemia unawareness was achieved by 3
months. In some but not all reports, the
recovery of symptoms is accompanied by
the improvement in epinephrine secre-
tion (32,33,120,121). The return of hy-
poglycemic symptom awareness was
associated with a modest increase (;0.5%)
in HbAlc values (33), but others have
reported no loss of glycemic control
(32,34).
Glucose monitoring
Glucose monitoring is essential in man-
aging patients at risk for hypoglycemia.
Patients treated with insulin, sulfonyl-
ureas, or glinides should check their blood
glucose whenever they develop the symp-
toms of hypoglycemia in order to conﬁrm
that they must ingest carbohydrates to
treat the symptoms and collect informa-
tion that can be used by the clinician to
adjust the therapeutic regimen to avoid
future hypoglycemia. Patients on basal-
bolus insulin therapy should check their
blood glucose before each meal and ﬁgure
this value into the calculation of the dose
of rapid-acting insulin to take at that time.
Such care in dosing will likely reduce the
risk of hypoglycemia.
Recent technological developments
have provided patients with new tools
for glucose monitoring. Real-time CGM,
by virtue of its ability to display the
direction and rate of change, provides
helpful information to the wearer leading
to proactive measures to avoid hypogly-
cemia, e.g., when to think about having a
Table 1dApproach to restore recognition of hypoglycemia in patients with HAAF
Monitoring and goal setting
Encourage SMBG before meals, at bedtime, and during suggestive symptoms
Encourage SMBG between 2 A.M. and 5 A.M. at least three times weekly
Set targets for preprandial blood glucose levels at 100–150 mg/dL
Patient education
Educate patients on hypoglycemic symptoms and the role of recurrent hypoglycemia in the
etiology of hypoglycemia unawareness
Reassure patients that hypoglycemia unawareness is reversible through avoidance of
hypoglycemia
Train patients to recognize and respond promptly to early neuroglycopenic symptoms
Dietary intervention
Ensure adequate caloric intake
Recommend interprandial and bedtime snacks
Ensure access to readily absorbable carbohydrates at all times
Consider moderate amounts of xanthine beverages, if tolerated
Exercise counseling
Encourage SMBG before, during, and after exercise
Advise preexercise caloric intake if blood glucose is ,140 mg/dL
Advise consumption of additional calories during and after exercise if blood glucose is,140
mg/dL
Medication adjustment
Adjust insulin regimen to achieve and maintain target glucose levels
Use rapid-acting insulin analogs (lispro, aspart, glulisine) to decrease the risk of interprandial
hypoglycemia
Use basal insulin analogs (glargine, detemir) to decrease the risk of nocturnal hypoglycemia
Consider a continuous subcutaneous insulin infusion pump, as appropriate
Consider a CGM device
Adapted from reference 125.
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snack or suspending insulin delivery on a
pump. The CGM’s audible and/or vibra-
tory alarms may be particularly helpful in
avoiding severe hypoglycemia at night
and restoring hypoglycemic awareness.
With the low-glucose alarms set at 108
mg/dL, 4 weeks of real-time CGM use re-
stored the epinephrine response and im-
proved adrenergic symptoms during a
hyperinsulinemic hypoglycemic clamp
in a small group of adolescents with
type 1 diabetes and hypoglycemic un-
awareness (122).
The artiﬁcial pancreas, which couples a
CGM to an insulin pump through sophis-
ticated predictive algorithms, holds out the
promise of completely eliminating hypo-
glycemia. Several internationally collabora-
tive groups are working on various
approaches to the artiﬁcial pancreas. The
ﬁrst step in this direction is the low-glucose
suspend pump that is available in Europe
and currently in clinical trials in the U.S.
This device shuts off insulin delivery for up
to 2 h once the interstitial glucose concen-
tration reaches a preset threshold and
reduces the duration of nocturnal hypo-
glycemia (123).
Clinical surveillance
Clinicians and educators must assess the
risk of hypoglycemia at every visit with
patients treated with insulin and insulin
secretagogues. An efﬁcient way to begin
this assessment might be to have the
patient complete the questionnaire
shown in Table 2 while in the waiting
room. Review of the completed ques-
tionnaire will help the clinician learn
how often the patient is experiencing
symptomatic and asymptomatic hypo-
glycemia, ensure the patient is aware of
how to appropriately treat hypoglyce-
mia, and remind both parties of the risks
associated with driving while hypogly-
cemic. To ensure that hypoglycemia
has been adequately addressed during
a visit, providers may want to use
the Hypoglycemia Provider Checklist
(Table 3).
A careful review of the glucose log
collected by the patient should also be
done at each visit. The date, approxi-
mate time, and circumstances surround-
ing recent episodes of hypoglycemia
should be noted, together with in-
formation regarding the awareness of
the warning symptoms of hypoglycemia.
A reliable history of impaired autonomic
responses (tremulousness, sweating, pal-
pitations, and hunger) during hypogly-
cemia may be the most practical
approach to making the diagnosis of
hypoglycemia unawareness. If symptoms
are absent or if frequent episodes of
recurrent hypoglycemia occur within
hours to days of each other, it is likely
that the patient has HAAF. Other his-
torical clues such as experiencing more
than one episode of severe hypoglycemia
that required the assistance of another
over the preceding year or a family re-
port that they are recognizing more
frequent episodes of hypoglycemia may
also provide clues that the patient has
developed hypoglycemia unawareness.
A self-reported history of impaired or
absent perception of autonomic symp-
toms during hypoglycemia correlates
strongly with laboratory conﬁrma-
tion of hypoglycemia unawareness
(33,121,124,125).
Table 2dHypoglycemia Patient Questionnaire
Name _____________________________________________________________________
First Middle Last
Today’s date __________
1. To what extent can you tell by your symptoms that your blood glucose is LOW?
____ Never ____ Rarely ____ Sometimes ____ Often ____ Always
2. In a typical week, how many times will your blood glucose go below 70 mg/dL?
______ a week
3. When your blood glucose goes below 70 mg/dL, what is the usual reason for this?
__________________________________________________________________________
4. How many times have you had a severe hypoglycemic episode (where you needed someone’s
help and were unable to treat yourself)?
Since the last visit ____ times
In the last year ____ times
5. How many times have you had a moderate hypoglycemic episode (where you could not think
clearly, properly control your body, had to stop what you were doing, but you were still able to
treat yourself)?
Since the last visit ____ times
In the last year ______ times
6. How often do you carry a snack or glucose tablets (or gel) with you to treat low blood glucose?
Check one of the following:
Never ___ Rarely ___ Sometimes___ Often___ Almost always___
7. How LOW does your blood glucose need to go before you think you should treat it?
Less than ____mg/dL
8. What and how much food or drink do you usually treat low blood glucose with?
__________________________________________________________________________
9. Do you check your blood glucose before driving? Check one of the following:
Yes, always___ Yes, sometimes ___ No___
10. How LOW does your blood glucose need to go before you think you should not drive?
____mg/dL
11. How many times have you had your blood glucose below 70 mg/dL while driving?
Since the last visit ____ times
In the last year ______ times
12. If you take insulin, do you have a glucagon emergency kit?
Yes___/ No ___
13. Does a spouse, relative, or other person close to you know how to administer glucagon?
Yes___/ No ___
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What are the current
knowledge gaps in our
understanding of
hypoglycemia, and what
research is necessary to ﬁll
these gaps?dSince the publication
of the previous report from the Work-
group on Hypoglycemia in 2005 (1),
much has been learned about the impact
of hypoglycemia on patient outcomes.
However, hypoglycemia continues to
cause considerable morbidity and even
mortality in patients with diabetes. If pa-
tients are to beneﬁt from the reduction in
microvascular complications that follows
from achieving near-normal levels of gly-
cemia, additional research will be neces-
sary to prevent them from experiencing
hypoglycemia and HAAF. First, new sur-
veillance methods that provide consistent
ways of reporting hypoglycemia must be
developed so that the impact of any in-
tervention to prevent and treat hypogly-
cemia can be fully assessed. Greater
attentionmust be focused on understand-
ing which patients are most at risk for
hypoglycemia and on developing new ed-
ucational strategies that effectively reduce
the number of episodes experienced by
at-risk patients. New therapies that do
not cause hypoglycemia, including an ar-
tiﬁcial pancreas, need to be developed for
both type 1 and type 2 diabetes. The tech-
nologies used to monitor blood glucose
must become more accurate, more reli-
able, easier to use, and less expensive.
The mechanisms that render patients un-
able to increase glucagon secretion in re-
sponse to hypoglycemia and that are
responsible for the development of
HAAF must be identiﬁed so strategies
can be developed to ensure that patients
always experience early warning signs
of impending neuroglycopenia. The im-
pact of hypoglycemia on short-term
outcomes such as mortality and long-
term outcomes such as cognitive dys-
function need to be better deﬁned, and
the mechanisms for these associations
need to be understood. Focused re-
search in these priority areas will address
our knowledge gaps about hypoglycemia
and ultimately reduce the impact of iat-
rogenic hypoglycemia on patients with
diabetes.
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